Adverse Events During Collection Phase
| Adverse Event . | Filgrastim Alone . | SCF and Filgrastim . | ||
|---|---|---|---|---|
| . | (n = 55, 10 μg/kg/d) . | (n = 160, 5-30 μg/kg/d) . | ||
| . | Related . | Overall . | Related . | Overall . |
| Injection site reactions | 2% | 5% | 88% | 88% |
| Musculoskeletal symptoms | 29% | 45% | 19% | 43% |
| Headache | 5% | 24% | 15% | 31% |
| Fever | 4% | 18% | 5% | 24% |
| Pruritus | 0% | 2% | 3% | 3% |
| Urticaria | 0% | 0% | 4% | 4% |
| Tachycardia | 0% | 16% | 3% | 31% |
| Chest pain | 2% | 7% | 4% | 6% |
| Ecchymosis | 2% | 4% | 3% | 8% |
| Dyspnea | 2% | 7% | 3% | 6% |
| Pain | 0% | 18% | 3% | 18% |
| Fatigue | 4% | 13% | 2% | 14% |
| Rash | 0% | 0% | 3% | 10% |
| Adverse Event . | Filgrastim Alone . | SCF and Filgrastim . | ||
|---|---|---|---|---|
| . | (n = 55, 10 μg/kg/d) . | (n = 160, 5-30 μg/kg/d) . | ||
| . | Related . | Overall . | Related . | Overall . |
| Injection site reactions | 2% | 5% | 88% | 88% |
| Musculoskeletal symptoms | 29% | 45% | 19% | 43% |
| Headache | 5% | 24% | 15% | 31% |
| Fever | 4% | 18% | 5% | 24% |
| Pruritus | 0% | 2% | 3% | 3% |
| Urticaria | 0% | 0% | 4% | 4% |
| Tachycardia | 0% | 16% | 3% | 31% |
| Chest pain | 2% | 7% | 4% | 6% |
| Ecchymosis | 2% | 4% | 3% | 8% |
| Dyspnea | 2% | 7% | 3% | 6% |
| Pain | 0% | 18% | 3% | 18% |
| Fatigue | 4% | 13% | 2% | 14% |
| Rash | 0% | 0% | 3% | 10% |
Adverse events, considered at least possibly related to cytokine administration, occurring in greater than 3% of patients during the collection phase; these are shown in descending order of event frequency in the combination cytokine group. The overall frequency of these events, regardless of relationship to cytokine, is also shown. The SCF alone patients (n = 5) are included with the combination cytokine patients.